Published online 2021 September 26.

Brief Report



Naphthalene Poisoning During a Decade: A Retrospective Clinical Study

Hoda Memar¹, Peyman Erfan Talab Evini², Golnar Seirafi³ and Mitra Rahimi ¹/₂, *

¹Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Toxicological Research Center, Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Tehran University of Medical Sciences, Tehran, Iran

Corresponding author: Department of Clinical Toxicology, Loghman-Hakim Hospital, 1333631151, Tehran, Iran. Tel/Fax: +98-2155424041 Email: mrahimi744@gmail.com

Received 2021 August 26; Accepted 2021 September 13.

Abstract

In this study, we investigated the naphthalene poisoning cases using the archived medical records of patients who were referred to Loghman-Hakim Hospital in Tehran, Iran, from 2008 to 2018. In the 52 studied cases, the highest prevalence was observed in the age groups of below five years and 20 - 25 years. Eighteen (34%) patients had no symptoms, and in others, gastrointestinal problems were the most common complaints. None of the patients needed intubation, and no one was admitted to the intensive care unit. Hemolysis was observed only in one patient with a background of G6PD deficiency. The average length of hospital stay was one day, and all patients improved without any complications. In general, naphthalene poisoning is not highly prevalent in Iran and usually does not cause severe morbidity and mortality. However, it is an available substance and can cause serious complications, especially in children. Therefore, it is necessary to investigate the clinical characteristics of these patients to improve the quality of health care.

Keywords: Naphthalene, Poisoning, Hemolysis, Glucosephosphate Dehydrogenase Deficiency

1. Background

Naphthalene is an aromatic hydrocarbon used in the production of plasticizers, resins, and insecticides, as well as in a variety of consumer products such as moth repellents (1). It is thought that a considerable source of non-occupational exposure in residential surroundings is due to the use of naphthalene-based products, particularly mothballs (2). The International Agency for Research on Cancer (IARC) and the US Environmental Protection Agency (USEPA) have classified naphthalene as a potential human carcinogen since 2000 (3).

Accidental or intentional poisoning by naphthalene has been reported by swallowing, skin contact, and inhalation. The metabolite of naphthalene (usually α -naphthol) is the main cause of poisoning. Exposure to naphthalene commonly causes headache, nausea, vomiting, diarrhea, abdominal pain, fever, and altered mental status. Hemolysis and methemoglobinemia usually become clinically evident, as early as 24 to 48 hours post-exposure. Patients with G6PD deficiency are at an increased risk of both hemolysis and methemoglobinemia (4). The estimated lethal dose of naphthalene is 5 - 15 grams for adults and 2 - 3 grams for children (5).

2. Objectives

To our knowledge, no study has been conducted on naphthalene poisoning in Iran so far. Therefore, the main purpose of this study was to investigate the clinical presentation and outcome of naphthalene poisoning.

3. Methods

This descriptive, retrospective study was done using the archived medical records of patients hospitalized in Loghman-Hakim hospital in Tehran, Iran, over 10 years (2008 - 2018). The research population included all patients hospitalized due to naphthalene poisoning. A data collection form was designed for this research that was filled based on the patients' medical files archived under the code T60.1. In general, 70 medical files were studied. After the exclusion of 18 cases because of multiple drug toxicity, 52 cases were included in the study. The collected data

Copyright © 2021, Trends in Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

were analyzed by SPSS version 25 software. We used the chisquare test for data analysis and P < 0.05 was defined as significant.

4. Results

In the 52 studied cases, 23 (44%) were females and 29 (56%) were males. The highest prevalence was observed in the age groups of below five years and 20 - 25 years. The average interval between taking naphthalene and admission to the hospital was 4.6 hours. All patients took naphthalene orally (mothball). The least number of taken mothballs was half a ball and the highest number was 20 naphthalene balls. The cause of poisoning was intentional in 34 (65%) cases and accidental in 18 (35%) cases. The clinical presentations are given in Figure 1. Impaired consciousness was not observed, and none of the patients needed intubation or admission to the intensive care unit.

The laboratory test results are given in Table 1. Among the 52 cases, hemolysis was observed only in one patient with a background of G6PD deficiency, which occurred 48 hours after poisoning. The duration of hospitalization was one day in 28 (54%) cases, less than one day in 19 (37%) cases, two days in four (8%) cases, and six days in one (2%) case. The medical treatment was supportive in 24 cases, charcoal in 22 cases, gastric lavage in five cases, and blood transfusion in one case. All patients were discharged from the hospital without any complications.

5. Discussion

In our study, most of the poisoning cases were observed in children, especially at the age below five years, which could be due to the use of naphthalene and its availability at home. Besides, a high prevalence rate was observed in the age group of 20 - 25 years, caused by the intentional use of naphthalene for committing suicide.

In a study in India, the prevalence of naphthalene poisoning was reported at 5% in home poisoning cases over 10 years (6). In a case report, a 10-year-old boy was affected by methemoglobinemia and hemolysis 48 hours after taking an uncertain amount of naphthalene ball (7). In another case report, naphthalene poisoning in a woman resulted in acute kidney failure and pulmonary edema in addition to hemolysis (8). In another study, a one-year-old child was affected by hemolysis, acute kidney failure, and pigmented nephropathy following ingestion of naphthalene balls (9). The occurrence of hemolysis is higher in patients with G6PD deficiency, as observed in a case report of a 15-year-old boy with hemolysis, methemoglobinemia, and kidney injury following the ingestion of a single naphthalene ball (10). Naphthalene toxicity has also been reported in a newborn baby with a history of maternal mothball ingestion (11). This study suggested the transplacental transfer of naphthalene. Also, some studies have shown the carcinogenicity of naphthalene in rats (12, 13). The noteworthy point is an average of 48 hours interval between taking naphthalene and hemolysis occurrence. It makes the clinical judgment difficult in the early hours.

The research constraints include the deficiency of information in medical records. Furthermore, as most cases were related to self-injury intention, it was not possible to investigate the patients directly.

In conclusion, naphthalene poisoning is not highly prevalent and it is not lethal in Iran. Besides, proper clinical judgment and treatment will lead to a good prognosis in most patients. The other important point is the necessity of a longer period of follow-up for patients who are prone to the occurrence of complications, such as patients with G6PD deficiency. It is also recommended to ban the sale of naphthalene, especially by groceries, and authorized sale centers must warn users

References

Footnotes

Authors' Contribution: Study concept and design, M.R.; Acquisition of data, H.M.; Analysis and interpretation of data, H. M. and G. S.; Drafting of the manuscript, G. S. and H.M.; Critical revision of the manuscript for important intellectual content, M. R. and P. E.; Statistical analysis, H. M.; Administrative, technical, and material support, M.R. and P.E; Study supervision, M.R.

Conflict of Interests: All authors declare that they have no conflict of interest.

Ethical Approval: This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran, under the Ethics code of IR.SBMU.MSP.REC.1397.142.

Funding/Support: This study was supported by the Clinical Research Development Unit of Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Uncorrected Proof






Figure 1. Clinical presentations

Table 1. Results of Laboratory Tests

| Laboratory test | Frequency | Percent |
|-----------------------------|-----------------|---------|
| CBC | | |
| Normal | 28 ^a | 53.8 |
| Leukocytosis | 6 | 11.5 |
| Anemia | 1 | 1.9 |
| Leukocytosis and Anemia | 2 | 3.8 |
| Missing | 15 | 28.8 |
| VBG | | |
| Normal | 17 | 32.7 |
| Abnormal | 13 | 25 |
| Missing | 22 | 42.3 |
| LDH | | |
| Normal | 9 | 17.3 |
| Elevated | 9 | 17.3 |
| Missing | 34 | 65.4 |
| СРК | | |
| Normal | 15 ^a | 28.8 |
| Elevated | 2 | 3.8 |
| Missing | 35 | 67.3 |
| Bilirubin | | |
| Normal | 19 ^a | 36.5 |
| Indirect Hyperbilirubinemia | 2 | 3.8 |
| Missing | 31 | 59.6 |
| Urine analysis | | |
| Normal | 15 ^a | 28.8 |
| Abnormal | 5 | 9.6 |
| Missing | 32 | 61.5 |

^a P < 0.05.

References

- El-Masri H; Agency for Toxic Substances and Disease Registry; Environmental Protection Agency; Syracuse Research Corporation. *Toxicological profile for naphthalene, 1-methylnaphthalene, and 2-methylnaphthalene.* Michigan,USA: Agency for Toxic Substances and Disease Registry; 2005.
- Sudakin DL, Stone DL, Power L. Naphthalene mothballs: Emerging and recurring issues and their relevance to environmental health. *Curr Top Toxicol.* 2011;7:13–9. [PubMed: 24319320]. [PubMed Central: PMC3850774].
- 3. Preuss R, Angerer J, Drexler H. Naphthalene–An environmental and occupational toxicant. *Int Arch Occup Environ Health*. 2003;**76**(8):556–76. doi: 10.1007/s00420-003-0458-1. [PubMed: 12920524].
- 4. Nelson LS, Howland MA, Lewin NA. *Goldfrank's toxicologic emergencies*. New York, USA: McGraw-Hill Education; 2019.
- Sandmeyer E, Clayton G, Clayton F. Aromatic Hydrocarbons. In: Clayton GD, Clayton FE, editors. *Patty's industrial hygiene and toxicology*. Sussex, UK: John Wiley & Sons Inc; 1981.
- Peshin SS, Gupta YK. Poisoning due to household products: A ten years retrospective analysis of telephone calls to the National Poisons Information Centre, All India Institute of Medical Sciences, New Delhi, India. J Forensic Leg Med. 2018;58:205–11. doi: 10.1016/j.jflm.2018.07.005. [PubMed: 30015223].
- Volney G, Tatusov M, Yen AC, Karamyan N. Naphthalene toxicity: Methemoglobinemia and acute intravascular hemolysis. *Cureus*. 2018;**10**(8). e3147. doi: 10.7759/cureus.3147. [PubMed: 30345203]. [PubMed Central: PMC6191007].

- Kundra TS, Bhutatani V, Gupta R, Kaur P. Naphthalene poisoning following ingestion of mothballs: A case report. *J Clin Diagn Res.* 2015;9(8):UD01-2. doi: 10.7860/JCDR/2015/15503.6274. [PubMed: 26436023]. [PubMed Central: PMC4576617].
- Ekambaram S, Chandan Kumar KM, Mahalingam V. Acute kidney injury: A rare complication of mothball (Naphthalene) poisoning. Saudi J Kidney Dis Transpl. 2017;28(6):1412-5. doi: 10.4103/1319-2442.220858. [PubMed: 29265056].
- Deo P, Sahu KK, Dhibar DP, Varma SC. Naphthalene ball poisoning: A rare cause of acquired methaemoglobinaemia. *BMJ Case Rep.* 2016;**2016**. doi: 10.1136/bcr-2016-215102. [PubMed: 27226127]. [PubMed Central: PMC4885267].
- Shafer G, Arunachalam A, Lohmann P. Newborn with perinatal naphthalene toxicity after maternal ingestion of mothballs during pregnancy. *Neonatology*. 2020;**117**(1):127–30. doi: 10.1159/000504345. [PubMed: 31751989].
- Bogen KT, Benson JM, Yost GS, Morris JB, Dahl AR, Clewell H3, et al. Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. *Regul Toxicol Pharmacol.* 2008;**51**(2 Suppl):S27–36. doi: 10.1016/j.yrtph.2007.10.018. [PubMed: 18191315]. [PubMed Central: PMC4030291].
- North DW, Abdo KM, Benson JM, Dahl AR, Morris JB, Renne R, et al. A review of whole animal bioassays of the carcinogenic potential of naphthalene. *Regul Toxicol Pharmacol.* 2008;51(2 Suppl):S6-14. doi: 10.1016/j.yrtph.2007.09.022. [PubMed: 18364246].